City of Hope | Strategic Alliance Partners

Surgery and radiation therapy are standard treatment options for localized prostate cancer, but are not comparative to one another.

Przemyslaw W. Twardowski, MD, director, Prostate Oncology Strategic Program, director, Genitourinary Program, clinical professor, Department of Medical Oncology and Therapeutics Research, medical oncologist, discusses the challenge with sequencing therapies for patients with metastatic castration-resistant prostate cancer (mCRPC).

Przemyslaw W. Twardowski, MD, describes the available therapies for patients with advanced metastatic castration-resistant prostate cancer, including bone-targeted therapies; the work that still lies ahead with these treatments; and the challenges with finding biomarkers to help develop targeted agents.

Perhaps oncologists know that having a detailed understanding of population-based survival statistics is very different from such knowledge of the future clinical course of an individual patient.

Sumanta Kumar Pal, MD, provides insight on the FDA approval of the TKI lenvatinib in combination with everolimus, an mTOR inhibitor as a treatment for patients with advanced RCC following prior antiangiogenic therapy.

Shouldn’t the goal of oncologists be to do what is best for their patients, regardless of the currently existing level of evidence and particularly when any timeline for obtaining that "gold standard" evidence will be irrelevant for the patient being cared for today?

If germline testing for a cancer-associated purpose reveals the risk of an unrelated illness like Alzheimer disease, should patients routinely be told—even if there’s nothing that can be done about that “incidental” finding?

The research will test how 8-chloro-adenosine functions in patients with refractory/relapsed AML.

The collaboration will bring together exceptional researchers from the United States and Israel.

The study calls for changes to reduce health disparities.

Although the goals of quality-care and value-based oncology initiatives are legitimate and laudable, some of the assertions should be examined more closely.

Thoracic specialist will guide expansion of clinical programs, integrate research into patient care.

City of Hope is offering an interactive educational conference for oncologists, hematologists and oncology nurses to learn about the latest advances in bone marrow transplants, as well as the treatment of leukemia, lymphoma and myeloma.

It is simply unrealistic and highly counterproductive to the future of cancer care to believe that the only acceptable approach to determining the absolute or relative clinical utility of a specific drug, regimen, device, or procedure, is through the conduct of a so-called evidence-based randomized trial.

Early promising responses seen with immune checkpoint inhibitors for patients with ovarian cancer still need to be validated in larger randomized trials before a conclusion is made regarding their true efficacy.

Examples of the clinical relevance of an individual patient's normal polymorphisms continue to mount.

How can any analysis of the quality of cancer care being delivered by providers that focuses on a survival outcome as the ultimate measure of that quality-rather than on an evaluation of the optimization of the care process-be considered objectively valid and clinically meaningful?

Maurie Markman, MD, discusses how the molecular complexities of cancer necessitate that clinical research evolves beyond the basket trial design.

The past decade has demonstrated a movement toward more extensive LND in order to sample and remove more lymph nodes.

Mathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses the impact of prostate-specific antigen (PSA) screening recommendations.

Mathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses prostate cancer screening.

Maurie Markman, MD, national director, Cancer Treatment Centers of America, discusses what he sees as future treatment paradigms in ovarian cancer.

For further insight into the evolving role of expanded mutation analysis in mCRC, OncLive interviewed Marwan G. Fakih, MD, the director of Gastrointestinal Medical Oncology at City of Hope.

Recent advancements in the treatment of ovarian cancer, including surgical techniques, the approvals of bevacizumab and olaparib, and intraperitoneal chemotherapy, have led the National Comprehensive Cancer Network to make changes to their clinical practice guidelines.

Joseph Alvarnas, MD, the director of Medical Quality at City of Hope National Medical Center, discusses autologous hematopoietic stem cell transplantation (AHCT) for patients with HIV-associated lymphoma.

Surgery remains the most effective curative treatment for esophageal cancer. Yet, many eligible patients do not undergo esophagectomy.

Karen L. Reckamp, MD, discusses the results of a phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who progressed on erlotinib.

Cabozantinib added to erlotinib has antitumor activity in heavily pretreated patients with EGFR-positive non–small cell lung cancer (NSCLC) whose disease progressed on erlotinib alone, according to the results of a phase II trial presented at the 2014 ASCO Annual Meeting.

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses the results of a retrospective analysis of the effect of prior abiraterone use on the activity level of enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC).

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses anti-angiogenesis versus anti-EGFR therapy in patients who have RAS wild-type colorectal cancer.